Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy

World Journal of Biological Psychiatry

Volumn 16, Issue 7, 2015, Pages 483-501

  Möller, Hans Jürgen ^a   Demyttenaere, Koen ^b   Olausson, Bengt ^c   Szamosi, Johan ^c   Wilson, Ellis ^d   Hosford, David ^e   Dunbar, Geoffrey ^e   Tummala, Raj ^d   Eriksson, Hans ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e TARGACEPT INC   (United States)

Author keywords

Adjunct therapy; antidepressant; major depressive disorder; nicotinic channel modulator; TC 5214

Indexed keywords

ALPRAZOLAM; DEXMECAMYLAMINE; ESTAZOLAM; ESZOPICLONE; IBUPROFEN; LORAZEPAM; MULTIVITAMIN; OXAZEPAM; PARACETAMOL; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE; ANTIDEPRESSANT AGENT; CITALOPRAM; MECAMYLAMINE; SERTRALINE;

ADD ON THERAPY; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONSTIPATION; DEPRESSED BLOOD PRESSURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; XEROSTOMIA; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MECAMYLAMINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946733760     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2014.989261     Document Type: Article

References (33)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. [Internet]. 2010 October. Available from: http://psychiatryonline.org/content.aspx?bookid-28§ionid-1667485
3. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. 2008. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343-396
4. Barnes TRE. 1989. Arating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
5. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67-104
6. Burman CF, Sonesson C, Guilbaud O. 2009. Arecycling framework for the construction of Bonferroni-based multiple tests. Stat Med 28:739-761
7. Clayton AH, McGarvey EL, Clavet GJ. 1997. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33:731-745
8. Daly EJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, et al. 2010. Health-related quality of life in depression: a STAR∗D report. Ann Clin Psychiatry 22:43-55
9. Dunbar G, Hosford D. 2010. The potential of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depression [abstract]. Eur Neuropsychopharmacol 20(Suppl 3):S334
10. Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321-326
11. EuroQol Group. 1990. EuroQol-a new facility for the measurement of health-related qualilty of life. Health Policy 16:199-208
12. Guy W. 1976a. Abnormal Involuntary Movement Scale (AIMS). In: ECDEUAssessment Manual for Psychopharmacology-Revised (DHEWPubl no ADM 766-338). Rockville, MD: USDepartment of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. p 534-537
13. Guy W. 1976b. Clinical global impressions. In: ECDEUAssessment Manual for Psychopharmacology. Washington, DC: USDepartment of Health, Education and Welfare. p 218-222
14. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
15. Hamilton M. 1960. Arating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
16. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. 1996. Comorbidity of DSM-III-Rmajor depressive disorder in the general population: results from the USNational Comorbidity Survey. Br J Psychiatry Suppl 168:17-30
17. Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, et al. 2008. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNSNeurosci Ther 14:266-277
18. Mineur YS, Picciotto MR. 2010. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580-586
19. Montgomery SA, Asberg M. 1979. Anew depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
20. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (National Clinical Practice Guideline 90) [Internet]. 2009 October. Available from: http://www.nice.org.uk/nicemedia/pdf/Depression-Update-FULL-GUIDELINE.pdf
21. Nemeroff CB. 2007. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17-25
22. Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. 2013. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol Biochem Behav 108:28-43
23. Papakostas GI, Charles D, Fava M. 2010. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? Ameta-analysis of randomised, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 11:300-307
24. Posner K, Oquendo M, Stanley B, Gould M. 2005. Suicidality Classification Project
25. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 44:77-87
26. Rush AJ. 2007. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 68(Suppl 10):8-10
27. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 163:1905-1917
28. Sheehan DV. 2000. Sheehan Disability Scale. In: Handbook of psychiatric measures. Washington, DC: American Psychiatric Association, pp. 113-115
29. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry 59(Suppl 20):22-33
30. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. 2002. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525-535
31. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, et al. 2010. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomised controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71:270-279
32. Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U, et al. 2014. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. European Neuropsychopharmacology 24:564-574
33. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. 2013. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150:384-388